- Home
- PEPG vs MAIA Comparison
PEPG vs MAIA Comparison
Compare PEPG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- MAIA
- Stock Information
- Founded
- PEPG 2018
- MAIA 2018
- Country
- PEPG United States
- MAIA United States
- Employees
- PEPG N/A
- MAIA N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- MAIA Health Care
- Exchange
- PEPG Nasdaq
- MAIA Nasdaq
- Market Cap
- PEPG 45.5M
- MAIA 46.7M
- IPO Year
- PEPG 2022
- MAIA 2022
- Fundamental
- Price
- PEPG $1.10
- MAIA $1.95
- Analyst Decision
- PEPG Buy
- MAIA
- Analyst Count
- PEPG 3
- MAIA 0
- Target Price
- PEPG $7.67
- MAIA N/A
- AVG Volume (30 Days)
- PEPG 261.3K
- MAIA 425.1K
- Earning Date
- PEPG 08-07-2025
- MAIA 08-08-2025
- Dividend Yield
- PEPG N/A
- MAIA N/A
- EPS Growth
- PEPG N/A
- MAIA N/A
- EPS
- PEPG N/A
- MAIA N/A
- Revenue
- PEPG N/A
- MAIA N/A
- Revenue This Year
- PEPG N/A
- MAIA N/A
- Revenue Next Year
- PEPG N/A
- MAIA N/A
- P/E Ratio
- PEPG N/A
- MAIA N/A
- Revenue Growth
- PEPG N/A
- MAIA N/A
- 52 Week Low
- PEPG $0.88
- MAIA $1.40
- 52 Week High
- PEPG $19.30
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- PEPG 29.69
- MAIA 61.28
- Support Level
- PEPG $1.10
- MAIA $1.60
- Resistance Level
- PEPG $1.49
- MAIA $1.95
- Average True Range (ATR)
- PEPG 0.10
- MAIA 0.11
- MACD
- PEPG -0.04
- MAIA 0.02
- Stochastic Oscillator
- PEPG 0.00
- MAIA 94.39
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.